SLS - SELLAS Life Sciences Group Inc (Healthcare: Biotechnology) Projected Earnings Date: 2024-08-12    (Delayed quote data   2025-06-27)
Last
 1.95		 Change
 ⇓ -0.08   (-3.94%)		 Volume
  15,867,404
Open
 2.01		 High
 2.04		 Low
 1.83
8EMA (Daily)
 1.81		 40EMA (Daily)
 1.63		 50EMA (Daily)
 1.60		 STO (Daily)
 94.953		 MACD Hist (Daily)
 0.077
8EMA (Weekly)
 1.669		 40EMA (Weekly)
 1.38		 50EMA (Weekly)
 1.37		 STO (Weekly)
 63.590		 MACD Hist (Weekly)
 0.075
Company Profile
SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com